Search results
Your search for TFRC returned no results
Showing 301 to 350 of 2467 results for term
Showing 301 to 350 of 2467 results for term
Gambling-related harms: identification, assessment and management (NG248)
This guideline covers identifying, assessing and treating gambling-related harms. This includes people aged 18 and over who are experiencing gambling that harms, and people of any age affected by someone close to them who is experiencing gambling that harms.
Preventing excess winter deaths and illness associated with cold homes (QS117)
This quality standard covers reducing the health risks (including preventable deaths) associated with cold homes. It includes identifying people at risk who are particularly vulnerable to the cold, such as young children, older people, and people with cardiovascular disease or mental health problems. It describes high-quality care in priority areas for improvement.
View quality statements for QS117Show all sections
Sections for QS117
- Quality statements
- Quality statement 1: Year-round planning to identify vulnerable local populations
- Quality statement 2: Identifying people vulnerable to health problems associated with a cold home
- Quality statement 3: Single-point-of-contact health and housing referral service
- Quality statement 4: Asking people about keeping warm at home
- Quality statement 5: Identifying people vulnerable to health problems associated with cold homes on admission
- Quality statement 6: Discharge plan
- About this quality standard
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)
Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children.
Adrenal insufficiency: identification and management (NG243)
This guideline covers identifying and managing adrenal insufficiency (hypoadrenalism) in babies, children, young people and adults. It aims to improve the treatment of primary, secondary and tertiary adrenal insufficiency, and the prevention and management of adrenal crisis.
Approaches for micro, small and medium-sized enterprises: What is the long-term effectiveness of universal individual-level...
its efficacy is inadequate in quality, particularly in terms of patient selection and long-term outcomes. Therefore, this...
Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)
Evidence-based recommendations on ravulizumab (Ultomiris) for treating atypical haemolytic uraemic syndrome in people weighing 10 kg or more.
Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Evidence-based recommendations on nivolumab (Opdivo) plus ipilimumab (Yervoy) for untreated unresectable or metastatic colorectal cancer with high microsatellite instability in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer.
People's experience using adult social care services (QS182)
This quality standard covers the experience of adults using social care services. It applies to all settings where people use social care services, including people's own homes, residential care and community settings. Its aim is to help people understand what care they can expect and to improve their experience by supporting them to make decisions about their care. It describes high-quality care in priority areas for improvement.
View quality statements for QS182Show all sections
Evidence-based recommendations on pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer in adults.
Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
Recommendation ID NG3/5 Question Are there effective long-term pharmacological interventions to prevent the onset of type 2 diabetes that
knee is limited in quality and quantity. Short-term evidence shows no major safety concerns, but long-term evidence on...
This quality standard covers preventing unintentional injury in children and young people (under 15). It includes local coordination of prevention strategies, and advice and assessment to help prevent accidents in the home. It describes high-quality care in priority areas for improvement.
View quality statements for QS107Show all sections
Sections for QS107
- Quality statements
- Quality statement 1: Coordinating action to prevent unintentional injuries
- Quality statement 2: Identifying households for a structured home safety assessment
- Quality statement 3: Structured home safety assessment
- Quality statement 4: Follow-up actions
- Quality statement 5: Integrating home safety into other visits
- About this quality standard
Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)
Evidence-based recommendations on nintedanib for treating progressive fibrosing interstitial lung diseases in adults.
Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.
Infliximab for acute exacerbations of ulcerative colitis (TA163)
Evidence-based recommendations on infliximab (Remicade) for treating acute exacerbations of severely active ulcerative colitis in adults.
of people with a Likert score on MRI of less than 3 without biopsy at long-term follow‑up? Any explanatory notes(if applicable) Why the...
organisations where employees are not centrally located to return to work after long-term sickness absence in the UK? Any explanatory...
This guideline covers identifying, treating and managing depression in people aged 18 and over. It recommends treatments for first episodes of depression and further-line treatments, and provides advice on preventing relapse, and managing chronic depression, psychotic depression and depression with a coexisting diagnosis of personality disorder.
This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.
Evidence-based recommendations on entecavir for treating chronic hepatitis B in adults.
replacement, what effect does anticoagulation or antiplatelet therapy have on long-term valve function and outcomes? Any explanatory...
NG212/01 Question Individual-level interventions: What is the long-term effectiveness and cost effectiveness of universal...
take the form of data collection, with the specific aim of documenting long-term outcomes and the need for further treatment. Any...
Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)
Evidence-based recommendations on ponesimod (Ponvory) for treating relapsing–remitting multiple sclerosis in adults.
Evidence-based recommendations on imlifidase (Idefirix) for desensitisation treatment before kidney transplant in people with chronic kidney disease.
Tocilizumab for the treatment of rheumatoid arthritis (TA247)
Evidence-based recommendations on tocilizumab (RoActemra) for treating rheumatoid arthritis in adults.
This quality standard covers assessing, diagnosing and managing rheumatoid arthritis in over 16s. It describes high-quality care in priority areas for improvement.
Vitamin B12 deficiency in over 16s: diagnosis and management (NG239)
This guideline covers recognising, diagnosing and managing vitamin B12 deficiency in people aged 16 and over, including deficiency caused by autoimmune gastritis. It also covers monitoring for gastric cancer in people with autoimmune gastritis.
Evidence-based recommendations on idebenone (Raxone) for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over.
Show all sections
Summary of the evidence on oral erythromycin for gastroparesis (delayed stomach emptying) in adults to inform local NHS planning and decision-making
Diabetes in pregnancy: management from preconception to the postnatal period (NG3)
This guideline covers managing diabetes and its complications in women who are planning pregnancy or are already pregnant. It aims to improve the diagnosis of gestational diabetes and help women with diabetes to self-manage their blood glucose levels before and during pregnancy.
This quality standard covers the period before, during and after a young person moves from children’s to adults’ services in all settings where transitions from children’s to adults’ health or social care services take place. It covers all young people (aged up to 25) using children’s health and social care services who are due to make the transition to adults’ services. This includes young people with mental health problems, disabilities and long-term, life-limiting or complex needs, rare diseases and those in secure settings or under the care of local authorities. It describes high-quality care in priority areas for improvement.
View quality statements for QS140Show all sections
Sections for QS140
- Quality statements
- Quality statement 1: Planning transition
- Quality statement 2: Coordinated transition plan
- Quality statement 3: Annual meeting
- Quality statement 4: Named worker
- Quality statement 5: Meeting a practitioner in adults' services
- Quality statement 6: Missed initial appointments after transfer to adults' services
- Update information
This quality standard covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It describes high-quality care in priority areas for improvement. It does not cover areas of national policy, such as the UK Bacillus Calmette-Guérin (BCG) immunisation programme.
View quality statements for QS141Show all sections
Sections for QS141
- Quality statements
- Quality statement 1: Latent tuberculosis testing for people from high-incidence countries
- Quality statement 2: Latent tuberculosis testing for adults with HIV
- Quality statement 3: Rapid diagnosis of pulmonary tuberculosis
- Quality statement 4: Assessment
- Quality statement 5: Directly observed therapy
- Quality statement 6: Accommodation
- Update information
Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus (HTG165)
Evidence-based recommendations on allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus. This involves removing cells called islet cells, which are responsible for the production of insulin, from human donors.
View recommendations for HTG165Show all sections
Sections for HTG165
Spesolimab for treating generalised pustular psoriasis flares (TA1070)
Evidence-based recommendations on spesolimab (Spevigo) for treating generalised pustular psoriasis flares in adults.
of discontinuing antipsychotic medication:- What are the short- and long-term benefits to physical health of guided medication...
reducing early and emerging behaviour that challenges in the short- and medium-term compared with treatment as usual? Any explanatory...
Indwelling urinary catheters: catheter selection:- For patients using a long-term indwelling urinary catheter, what is the clinical and...
NG223/11 Question Impact of COVID-19: What is the medium-to long-term impact of the COVID-19 pandemic on children and young people's...
enlargement), improvement in lower urinary tract symptoms in the short term and long term, re-intervention rates, and...
Percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction (HTG297)
Evidence-based recommendations on percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction. This involves implanting a replacement valve with a wire mesh tube called a stent.
View recommendations for HTG297Show all sections
Sections for HTG297
selection and the types of chondral defects being treated. More evidence on long-term outcomes would be useful. Any explanatory notes(if...
Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making
Infliximab and adalimumab for the treatment of Crohn's disease (TA187)
Evidence-based recommendations on infliximab (Remicade) and adalimumab (Humira) for treating severe active Crohn's disease in adults.
Evidence-based recommendations on eliglustat (Cerdelga) for treating type 1 Gaucher disease in adults.
Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (TA707)
Evidence-based recommendations on Nivolumab (Opdivo) for previously treated unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma in adults.